Managed care organizations must move beyond early, low-risk artificial intelligence (AI) use to strategically governed, ...
Rising Specialty Drug Costs and Co-Pay Models Raise Access Concerns: Patty Taddei-Allen, PharmD, MBA
In addition to the models, Taddei-Allen also pointed out the overall shift in employer plan drug costs, shifting more of the ...
Adam Colburn, JD, highlights 3 federal bills to expand value-based care, digital therapeutics, and pharmacist reimbursement ...
Results released April 1, 2026, by the American Society for Radiation Oncology (ASTRO), which represents more than 10,000 ...
Steven Kheloussi, PharmD, explains how care coordination and transparent policies can improve MS treatment adherence, ...
EHR validation in 406,230 “relaxed” and 127,151 “strict” patients showed stable PREVENT discrimination across sexes, ...
A 1000 mg ×2 induction regimen followed by maintenance every 6–12 months was associated with near-elimination of relapse ...
A breast cancer diagnosis doesn't land only on the patient, but rather it ripples through an entire household. In this ...
Prior authorization was rated a major burden by 32% of insured adults and the single greatest barrier by 34%, surpassing ...
A new case-control study published in JAMA Cardiology demonstrates that molecular imaging using gallium-68–labeled fibroblast ...
Midterm messaging is likely to center on health care costs, with Republicans emphasizing DTC drug models and MFN pricing ...
The pace of oncology innovation has accelerated beyond managed care's capacity to keep up, with gaps persisting across ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results